Cream vs. monitoring for mild cervical cell changes
Part of Women’s health & pregnancy clinical trials.
This study compares a cream called MODUCARE with simply monitoring CIN1 (mild cervical cell changes) to see which approach works better. If you have this mild diagnosis but haven't had major cervical treatment before, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a cervical biopsy showing CIN1 (mild changes).
- Can be any HPV status (negative, positive for high or low risk).
- Able to walk around and take care of yourself (ECOG 0 or 1).
- Age between 18 and 85 years old.
- Not pregnant.
- No previous cervical surgery, pelvic cancer, or severe cervical changes (CIN2/3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for ways to predict who will respond to imiquimod cream for precancerous cervical cell changes (CIN2 or CIN3). Results may help doctors choose the best treatment approach and better plan follow-up.
This trial tests whether a topical cream called TCA (trichloroacetic acid) can effectively treat low-grade cervical lesions (LSIL) found after an abnormal Pap or HPV test. It may be an option for women who want to avoid more invasive procedures.
This study tests whether a vaginal gel can help early cervical cell changes (CIN1 or CIN2) go away on their own and clear the HPV virus. If you are being monitored without treatment, this gel might increase your chances of recovery.
This study tests whether honey applied directly to the cervix can help reverse moderate cervical cell changes (CIN II). It may offer a natural alternative to more invasive procedures.
This Phase 2 study tests whether a curcumin (a natural plant compound) cream/gel applied to the cervix can help treat cervical cell changes linked to HPV. It focuses on people with mild (LSIL) or recently treated severe (HSIL) precancer changes, aiming to reduce disease and improve healing.
This study tests a new tool called PreCursor-M+® to see how well it helps doctors manage CIN2, a moderate cervical cell change. It’s for people who have already been diagnosed with CIN2 and know their HPV test results.
Hear when a new Low-grade Cervical Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.